Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of docetaxel-PM plus oxaliplatin in esophageal squamous cell carcinoma
KCT0003355Phase 2Completed
- Sponsor
- Dong-A University Hospital
- Start
- Jun 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Nanoxel M, oxaliplatin in Esophageal Squamous Cell Carcinoma (ESCC), Esophagogastric junction squamous cell carcinoma, sponsored by Dong-A University Hospital. Started Jun 2018; status: completed.
02
Drugs
Nanoxel Moxaliplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)Esophagogastric junction squamous cell carcinoma
Beyond the preview
Go deeper on KCT0003355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003355.